SuperGen Submits First NDA Module for Pancreatic Cancer Drug

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 2
Volume 12
Issue 2

DUBLIN, California-Super-Gen Inc. has begun submission of a New Drug Application (NDA) for Orathecin, an oral camptothecin, for the treatment of pancreatic cancer patients who are refractory/resistant to available therapies. The submission will occur on a rolling basis and is ex-pected to be completed by the end of the first quarter of 2003. The submission will contain data on more than 2,700 patients treated under Orathecin study protocols, the company said in a news release.

DUBLIN, California—Super-Gen Inc. has begun submission of a New Drug Application (NDA) for Orathecin, an oral camptothecin, for the treatment of pancreatic cancer patients who are refractory/resistant to available therapies. The submission will occur on a rolling basis and is ex-pected to be completed by the end of the first quarter of 2003. The submission will contain data on more than 2,700 patients treated under Orathecin study protocols, the company said in a news release.

Articles in this issue
COX-2 Inhibitors Decrease Toxicity due to Chemotherapy; May Help Arrest Tumor Progression
Some Activity for Gefitinib in Heavily Pretreated Breast Cancer
Brachytherapy Results Similar for Blacks, Whites
Dose-Dense Chemo Ups Survival in Node+ Breast Cancer
MR Spectroscopy IDs Breast Cancers, Node Involvement
ODAC Wants More Data on Expanded Casodex Indication
SuperGen Submits First NDA Module for Pancreatic Cancer Drug
Two Added to ONI’s Oncology Nursing Editorial Advisory Board
Bortezomib Active in Relapsed/Refractory Myeloma
Telomerase Potential Cancer Biomarker
Developing Targeted Therapy More Difficult Than Anticipated
Preoperative Chemoradiotherapy Downsizes 100% of Rectal Tumors in Phase I/II Trial
Fluorouracil/Leucovorin Maintains Leading Role, Results of Three-Drug Regimens Are Pending
Adjuvant Therapy for Rectal Cancer Still Needed in Node-Positive Cases
Adding Bevacizumab to IFL Combination Does Not Significantly Alter IFL Toxicity
Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
Related Content
Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.

TTFields Combo Shows Meaningful Benefits in Pancreatic Adenocarcinoma

Russ Conroy
August 7th 2025
Article

Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Phase 2 CRDF-004 results revealed that the addition of onvansertib to chemotherapy/bevacizumab was well-tolerated, with no unexpected toxicities observed.

Onvansertib Exhibits Encouraging Responses in RAS-Mutant Metastatic CRC

Roman Fabbricatore
July 30th 2025
Article

Phase 2 CRDF-004 results revealed that adding onvansertib to chemotherapy/bevacizumab was well tolerated, with no unexpected toxicities observed.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC

Tim Cortese
July 25th 2025
Article

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET

Tim Cortese
July 25th 2025
Article

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.